Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
09/08/2024 14:31
* Black Diamond Therapeutics Inc BDTX.OQ reported a
quarterly
adjusted loss of 36 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -52 cents. The mean expectation of
seven analysts for the quarter was for a loss of 39 cents per
share. Wall Street expected results to range from -43 cents
to -35 cents per share.
* Reported revenue was zero; analysts expected zero.
* Black Diamond Therapeutics Inc's reported EPS for the
quarter
was a loss of 36 cents.
* The company reported a quarterly loss of $19.91 million.
* Black Diamond Therapeutics Inc shares had risen by 4.0%
this
quarter and gained 72.4% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 2.4%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Black Diamond
Therapeutics Inc is $13.50
This summary was machine generated from LSEG data August 9 at
01:30 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.39 -0.36 Beat
Mar. 31 2024 -0.43 -0.35 Beat
Dec. 31 2023 -0.47 -0.34 Beat
Sep. 30 2023 -0.49 -0.45 Beat